Abstract
Antibody Drug Conjugates (ADCs) use targeting ability of monoclonal antibodies to deliver potent cytototoxic payloads to their intended target. The linker encompasses a conjugating functionality suitable for attachment to the antibody, a spacer unit that typically incorporates a hydrophilic element and a trigger which releases the potent cytototoxic warhead. Understanding the conflicting requirements of ADC design, providing stability in systemic circulation but efficient payload release once the ADC reaches its intended target, is crucial to effective linker development. ADC linker design has been approached in a variety of different ways, with increasingly elegant solutions continuing to be reported as understanding of the intricate design complexities increases. This review focuses on the synthetic approaches used in ADC linkers, and the impact of linker design on antibody conjugation, ADC pharmacokinetics and payload release. Linker approaches utilized in commercial ADCs as well as ADCs currently in clinical, pre-clinical and early stage development are discussed.
Keywords: Antibody Drug Conjugate, Linker Design, Conjugation Technologies, Disulfide Rebridging, Release Mechanism, Toxin Specific Linkers.
Current Topics in Medicinal Chemistry
Title:The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
Volume: 17 Issue: 32
Author(s): Mark Frigerio*Andrew F. Kyle
Affiliation:
- Abzena, Babraham Research Campus, Babraham, Cambridge, CB22 3AT,United Kingdom
Keywords: Antibody Drug Conjugate, Linker Design, Conjugation Technologies, Disulfide Rebridging, Release Mechanism, Toxin Specific Linkers.
Abstract: Antibody Drug Conjugates (ADCs) use targeting ability of monoclonal antibodies to deliver potent cytototoxic payloads to their intended target. The linker encompasses a conjugating functionality suitable for attachment to the antibody, a spacer unit that typically incorporates a hydrophilic element and a trigger which releases the potent cytototoxic warhead. Understanding the conflicting requirements of ADC design, providing stability in systemic circulation but efficient payload release once the ADC reaches its intended target, is crucial to effective linker development. ADC linker design has been approached in a variety of different ways, with increasingly elegant solutions continuing to be reported as understanding of the intricate design complexities increases. This review focuses on the synthetic approaches used in ADC linkers, and the impact of linker design on antibody conjugation, ADC pharmacokinetics and payload release. Linker approaches utilized in commercial ADCs as well as ADCs currently in clinical, pre-clinical and early stage development are discussed.
Export Options
About this article
Cite this article as:
Frigerio Mark *, Kyle F. Andrew , The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates, Current Topics in Medicinal Chemistry 2017; 17 (32) . https://dx.doi.org/10.2174/1568026618666180118155847
DOI https://dx.doi.org/10.2174/1568026618666180118155847 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Perspective on the Role of Four Beta-blockers in Heart Failure
Current Reviews in Clinical and Experimental Pharmacology Efficacy and Complications of Subcutaneous <i>versus</i> Conventional Cardioverter Defibrillators: A Systematic Review and Meta-analysis
Current Cardiology Reviews Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Breath Tests to Assess Alcoholic Liver Disease
Reviews on Recent Clinical Trials Patent Selections
Recent Patents on Cardiovascular Drug Discovery Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Risk Prediction Models and Scores in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease
Current Vascular Pharmacology Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Isosteviol Protects H9c2 Cells Against Hypoxia-reoxygenation by Activating ERK1/2
Cardiovascular & Hematological Disorders-Drug Targets Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Biomarkers in Acute Heart Failure Syndromes: An Update
Current Cardiology Reviews Role of miRNAs in Muscle Stem Cell Biology: Proliferation, Differentiation and Death
Current Pharmaceutical Design PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine